Medical device technology developer BrightWater Medical said that three studies involving its ConvertX nephroureteral stent system will be presented this week at the Society of Interventional Radiology (SIR) annual meeting in Vancouver, Canada.
The three preclinical model studies showed that it was feasible to use ConvertX to convert an internal-external nephroureteral catheter into an internal nephroureteral stent without an invasive procedure, according to the vendor. All conversions were successful in the three studies, and no stent migration, blockage, encrustation, sedimentation, fracture, or deformation was reported, BrightWater said.
ConvertX is designed to eliminate the need for a second invasive interventional procedure in the more than 300,000 patients each year who are treated for severe ureteral obstructions, the company said.
